This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Continuation therapy to eliminate residual disease

Authoring team

Continuation of treatment is necessary to prevent or forestall relapses in patients with ALL.

  • all cases should receive chemotherapy for 2 - 2·5 years
  • usual regimens consist of daily mercaptopurine and weekly methotrexate

When using mercaptopurine, patients should be informed that the dose should be taken in the evening (than in the morning) and to avoid taking it with milk or milk products that contain xanthine oxidase (2).

Thioguanine has been shown to be superior to mercaptopurine, but the side effects have limited its use. Thoiguanine may be used in short term courses during the intensification phase of treatment (1). Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.